Catatan sumber primer

PenentuSurat tanggapan lengkap

Achieve Life Sciences, Inc. · surat respons lengkap (NDA 218995)

FDA mengeluarkan surat respons lengkap untuk NDA 218995 tertanggal 2026-06-20.

Fakta utama

Diajukan
20 Jun 2026, 00.00
Peristiwa
Surat tanggapan lengkap
Arah
Negatif
Sumber
openFDA
Keyakinan
Bersumber

Kutipan sumber

ADMINISTRATION i Lk YN U.S. FOOD & DRUG NDA 218995 COMPLETE RESPONSE Achieve Life Sciences, Inc. 22722 29th Dr. SE, Suite 100 Bothell, WA 98021 Attention: | Sarah Telzrow Vice President, Regulatory Affairs Dear Sarah Telzrow: Please refer to your new drug application (NDA) dated and received June 20, 2025, and your amendments, submitted under for cytisinicline tablet, © . We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues. FACILITY INSPECTIONS (1) Following a CGMP inspection of Loey listed in this application, FDA conveyed deficiencies to the representative of the facilit

openFDA